GET DAILY SIGNALSNeumora Therapeutics (NMRA) Shares Slide -47% Over the Past Month Following Clinical Setbacks
Key Takeaways
- Neumora Therapeutics (NMRA) fell roughly 47% over the trailing 30 days, sliding from about $0.69 to approximately $0.37 per share.
- The decline extends the selloff that followed the discontinuation of lead candidate navacaprant after Phase 3 KOASTAL-2 and KOASTAL-3 trial failures in major depressive disorder.
- Shares have traded below $1.00, raising Nasdaq minimum-bid-price compliance concerns and contributing to forced selling by certain institutional funds.
- Over the last quarter, NMRA is down roughly 78%, reflecting a market re-rating from a late-stage depression program to an earlier-stage neuroscience pipeline.
- Analysts have lowered price targets but largely retain a "Moderate Buy" consensus as the company refocuses on NMRA-511, NMRA-898, and NMRA-215.
- For additional detail, explore Neumora's Price Targets, Earnings, and Forecast pages.
Company Background and Pipeline Focus
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It applies a precision-neuroscience strategy to develop brain-penetrant treatments for neuropsychiatric, neurodegenerative, and metabolic conditions. The current pipeline centers on NMRA-511 for agitation in Alzheimer's disease, NMRA-898 for schizophrenia, and NMRA-215 for obesity and related cardiometabolic issues. The company went public in September 2023 and remains pre-revenue, relying on cash reserves and a loan facility. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Moves: 30 Days and the Quarter
Over the last 30 days, NMRA declined roughly 47%, falling from a closing price near $0.69 to approximately $0.37. The move was mostly one-directional, with occasional bounces on higher volume that failed to hold. The drop picked up pace in mid-October as the stock moved from around $0.48 down toward $0.35.
The quarterly view shows an even sharper decline. From a closing price near $1.68 at the end of July, the shares are down roughly 78% over three months. This reflects a clear re-rating after the most advanced program was halted, leaving earlier-stage assets with longer timelines and more uncertainty.
Factors Behind the 30-Day Decline
The recent drop stems mainly from the ongoing impact of earlier clinical news rather than any single new event. After navacaprant was discontinued in June following the KOASTAL-2 and KOASTAL-3 Phase 3 failures, investor sentiment weakened steadily. The stock drifted lower as the market reassessed the risk profile of what remained in the pipeline.
Additional pressure came from the share price falling below $1.00, which triggered Nasdaq minimum-bid-price compliance worries and prompted mechanical selling from some funds. Research coverage added to the weight, including a downgrade to a "Strong Sell" rating in early October. Insider sales of roughly 450,000 shares over the trailing 90 days also weighed on sentiment. With no near-term Phase 3 catalyst in sight, the shares have continued to move closer to the company’s estimated cash value.
Drivers of the Quarterly Performance
The larger quarterly decline traces directly to the decision to discontinue navacaprant after the Phase 3 KOASTAL-2 and KOASTAL-3 studies in major depressive disorder missed statistical significance on primary and key secondary endpoints. Neumora responded with a workforce reduction of about 35% aimed at roughly $10 million in annual cost savings and a shift toward the remaining programs.
Analysts cut price targets sharply, moving several into the single digits from much higher prior levels, though most kept Buy or Outperform ratings tied to the early-stage assets. The loss of a late-stage opportunity, fewer near-term catalysts, and ongoing questions around clinical and financing timelines have driven the sustained decline.
What to Watch Going Forward
Investors should keep an eye on the next quarterly earnings report and any updates on cash runway and restructuring progress. The company has said its cash position could support operations into the third quarter of 2027, but future financing needs remain a notable risk for a pre-revenue business.
Pipeline updates will matter most. Early data on NMRA-898 in schizophrenia and further progress on NMRA-511 in Alzheimer's agitation are expected as the company advances its programs. The path for NMRA-215 in obesity, which has encountered prior toxicology issues, will also be important. Competitive dynamics in neuroscience and metabolic disease, regulatory developments, and any resolution of Nasdaq compliance questions could influence sentiment in the quarters ahead. I checked recent signals using Tickeron’s AI Daily Buy/Sell Signals to stay on top of broader market context.
AI Tools for Deeper Market Analysis
In my own research process, I’ve found Tickeron’s AI Trading Bots helpful for spotting systematic patterns across a wide range of tickers. The platform offers hundreds of automated strategies that can be filtered by performance, timeframe, and approach, which makes it easier to identify ideas that align with specific objectives without starting from scratch every time. This kind of data-driven view complements traditional fundamental work when evaluating names like NMRA that are in transition.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NMRA in +33.65% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NMRA advanced for three days, in 146 of 167 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NMRA's RSI Oscillator exited the oversold zone, 16 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for NMRA just turned positive on October 08, 2026. Looking at past instances where NMRA's MACD turned positive, the stock continued to rise in 16 of 20 cases over the following month. The odds of a continued upward trend are 80%.
NMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 35 cases where NMRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for NMRA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.554) is normal, around the industry mean (3.037). P/E Ratio (-0.299) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. NMRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement